Real-World Effectiveness of Lenvatinib in Hepatocellular Carcinoma Patients with Nonalcoholic Steatohepatitis

被引：3
|
作者：
Singal, Amit G. [1 ,4 ]
Nagar, Saurabh P. [2 ]
Hitchens, Abby [2 ]
Davis, Keith L. [2 ]
Iyer, Shrividya [2 ,3 ]
机构：
[1] UT Southwestern Med Ctr Dallas, Div Digest & Liver Dis, Dallas, TX USA
[2] RTI Hlth Solut, Res Triangle Pk, NC USA
[3] Eisai Inc, Woodcliff Lake, NJ USA
[4] Digest Dis Ctr, Div Digest & Singal, 5323 Harry Hines Blvd, Dallas, TX 75390 USA
来源：
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | 2023年 / 21卷 / 03期
关键词：
SORAFENIB;
D O I：
10.1016/j.cgh.2021.11.020
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
    Chiang, Hsueh-Chien
    Lee, Yang-Cheng
    Chang, Ting-Tsung
    Lin, Yih-Jyh
    Wu, Hung-Tsung
    Wang, Chung-Teng
    Chen, Chiung-Yu
    Chen, Po-Jun
    Hsieh, Ming-Tsung
    Lin, Sheng-Hsiang
    Chen, Shang-Hung
    Chuang, Chiao-Hsiung
    Wu, I-Chin
    Hong, Tzu-Chun
    Wu, Juei-Seng
    Han, Meng-Zhi
    Chen, Wei-Ting
    Chiang, Chien-Ming
    Hung, Kuan-Kai
    Kuo, Hsin-Yu
    CANCERS, 2023, 15 (03)
  • [22] Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan
    Furuse, Junji
    Izumi, Namiki
    Motomura, Kenta
    Inaba, Yoshitaka
    Katamura, Yoshio
    Kondo, Yasuteru
    Yabushita, Kazuhisa
    Motoyoshi, Katsuaki
    Kudo, Masatoshi
    DRUGS-REAL WORLD OUTCOMES, 2023, 10 (02) : 195 - 205
  • [23] Real-world effectiveness of lenvatinib monotherapy among previously treated unresectable hepatocellular carcinoma patients in United States clinical practices.
    Singal, Amit G.
    Nagar, Saurabh P.
    Hitchens, Abigail
    Iyer, Shrividya
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan
    Junji Furuse
    Namiki Izumi
    Kenta Motomura
    Yoshitaka Inaba
    Yoshio Katamura
    Yasuteru Kondo
    Kazuhisa Yabushita
    Katsuaki Motoyoshi
    Masatoshi Kudo
    Drugs - Real World Outcomes, 2023, 10 : 195 - 205
  • [25] Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma:A retrospective,real-world study conducted in China
    Dong-Xu Wang
    Xu Yang
    Jian-Zhen Lin
    Yi Bai
    Jun-Yu Long
    Xiao-Bo Yang
    Samuel Seery
    Hai-Tao Zhao
    World Journal of Gastroenterology, 2020, (30) : 4465 - 4478
  • [26] Population Pharmacokinetic Modeling of Lenvatinib in Chinese Patients With Advanced Hepatocellular Carcinoma Using Real-World Data
    Hu, Yingying
    Chen, Ruijia
    Ye, Zhenjie
    Wei, Fuqun
    Lin, Kecan
    Liu, Jingfeng
    Zeng, Yongyi
    JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (12): : 1507 - 1517
  • [27] Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis
    Cheon, Jaekyung
    Chon, Hong Jae
    Bang, Yeonghak
    Park, Neung Hwa
    Shin, Jung Woo
    Kim, Kang Mo
    Lee, Han Chu
    Lee, Jooho
    Yoo, Changhoon
    Ryoo, Baek-Yeol
    LIVER CANCER, 2020, 9 (05) : 613 - 624
  • [28] Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice
    Chen, Kang
    Wei, Wei
    Liu, Lei
    Deng, Zhu-Jian
    Li, Le
    Liang, Xiu-Mei
    Guo, Ping-Ping
    Qi, Lu-Nan
    Zhang, Zhi-Ming
    Gong, Wen-Feng
    Huang, Shan
    Yuan, Wei-Ping
    Ma, Liang
    Xiang, Bang-De
    Li, Le-Qun
    Zhong, Jian-Hong
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (05) : 1063 - 1074
  • [29] Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice
    Kang Chen
    Wei Wei
    Lei Liu
    Zhu-Jian Deng
    Le Li
    Xiu-Mei Liang
    Ping-Ping Guo
    Lu-Nan Qi
    Zhi-Ming Zhang
    Wen-Feng Gong
    Shan Huang
    Wei-Ping Yuan
    Liang Ma
    Bang-De Xiang
    Le-Qun Li
    Jian-Hong Zhong
    Cancer Immunology, Immunotherapy, 2022, 71 : 1063 - 1074
  • [30] Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study
    Persano, Mara
    Rimini, Margherita
    Tada, Toshifumi
    Suda, Goki
    Shimose, Shigeo
    Kudo, Masatoshi
    Cheon, Jaekyung
    Finkelmeier, Fabian
    Lim, Ho Yeong
    Rimassa, Lorenza
    Presa, Jose
    Masi, Gianluca
    Yoo, Changhoon
    Lonardi, Sara
    Tovoli, Francesco
    Kumada, Takashi
    Sakamoto, Naoya
    Iwamoto, Hideki
    Aoki, Tomoko
    Chon, Hong Jae
    Himmelsbach, Vera
    Pressiani, Tiziana
    Kawaguchi, Takumi
    Montes, Margarida
    Vivaldi, Caterina
    Solda, Caterina
    Piscaglia, Fabio
    Hiraoka, Atsushi
    Sho, Takuya
    Niizeki, Takashi
    Nishida, Naoshi
    Steup, Christoph
    Iavarone, Massimo
    Di Costanzo, Giovanni
    Marra, Fabio
    Scartozzi, Mario
    Tamburini, Emiliano
    Cabibbo, Giuseppe
    Foschi, Francesco Giuseppe
    Silletta, Marianna
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (09) : 5591 - 5602
12345